eMedicine Specialties > Infectious Diseases > Parasitic Infections

Ascariasis: Treatment & Medication

Author: David R Haburchak, MD, Program Director, Professor, Department of Internal Medicine, Division of Infectious Disease, Medical College of Georgia
Contributor Information and Disclosures

Updated: Sep 12, 2008

Treatment

Medical Care

Because of the risk of complications, patients with ascariasis who have other concomitant helminthic infections should always undergo treatment for ascariasis first. Medical therapy is usually not indicated during active pulmonary infection because dying larvae are considered a higher risk for significant pneumonitis. Pulmonary symptoms may be ameliorated with inhaled bronchodilator therapy or corticosteroids, if necessary.

  • Albendazole 400 mg one dose orally is the drug of choice. Ascariasis commonly coexists with whipworm infection, which appears to be more susceptible to albendazole than to mebendazole. Albendazole is not recommended during pregnancy; pyrantel pamoate is the drug of choice in these cases.
  • Alternative therapy is mebendazole (100 mg bid for 3 d or 500 mg as a single dose). Mebendazole is not recommended during pregnancy; pyrantel pamoate is the drug of choice in these cases.
  • Paralyzing vermifuges (eg, pyrantel pamoate, piperazine, ivermectin) should be avoided in patients with complete or partial intestinal obstruction since the paralyzed worms may necessitate or further complicate surgery.
  • Vitamin A supplementation improved growth development of children in Zaire; deworming did not improve growth development in this study.13
  • Drug therapy affects only adult worms. If the patient lives in an endemic area or has recently relocated, he or she may still be carrying larvae that are not yet susceptible. Such patients should be re-evaluated in 3 months and retreated if stool ova persist. In endemic areas, reinfection rates approach 80% within 6 months.
  • Nitazoxanide, a drug used primarily for protozoal infection, was shown to have 89% clinical efficacy for the treatment of ascariasis in rural Mexico and may offer a future alternative to other medications.14

Surgical Care

Conservative management of partial intestinal obstruction and biliary ascariasis is usually effective. The patient is maintained on nothing-by-mouth status, and the partial obstruction usually spontaneously resolves. Preventing oral intake decreases the risk of food compounding the obstruction while normal peristalsis redistributes or evacuates the worms. A controlled trial from Pakistan found that, in patients without peritonitis, hypertonic saline enemas relieved obstruction more quickly (1.6 d vs 3.4 d) and resulted in shorter hospital stays (4 d vs 6 d) than intravenous fluids alone. A recent study from India demonstrated that conservative therapy was successful in 19 of 22 (89%) children with intestinal obstruction. The regimen used consisted of no oral intake, intravenous fluids, antibiotics, piperazine salt per nasogastric tube, and glycerine plus liquid paraffin emulsion enemas.9

  • Recommended criteria for surgical exploration include the following:
    • Passage of blood per rectum
    • Multiple air fluid levels on abdominal radiographs
    • An ill child with abdominal distension and rebound tenderness
    • Unsatisfactory response to conservative therapy
    • Appendicitis and primary peritonitis
    • Hepatobiliary disease
    • Pancreatic pseudocyst
  • Most (49-90%) worms eventually migrate from the biliary system spontaneously. Drug therapy should be delayed in patients with right upper quadrant or pancreatic pain, as no evidence has shown that drugs are active against worms located in the biliary tree. Regardless, death of the worm in the duct may provoke both inflammation and obstruction. Patients with ascariasis who have only minor symptoms can undergo observation for 3 days. If the minor symptoms persist after 3 days or the patient develops frank cholangitis or pancreatitis, removal of the worms with ERCP should be attempted, if available. Although technically challenging at times, ERCP extraction rates have exceeded 90%.11
  • Intestinal or biliary surgery may be necessary for complications of ascariasis.
    • Intestinal gangrene usually occurs at the terminal ileum, more often after the use of pyrantel pamoate, which tetanically paralyzes worms and thereby enhances the risk of obstruction. Recently, 2 cases of delayed distal intestinal disease have been reported, which were thought to be secondary to toxins from the worms. Therefore, patients should probably be monitored for some time after the surgical removal of worms.
    • Milking of worms to the large bowel, resection of gangrenous bowel, ileostomy, and enterotomy are the most common surgical procedures used to manage bowel obstruction.
    • Invasion of the gall bladder necessitates cholecystectomy, common duct exploration, and T-tube drainage until the patient is stabilized and dewormed.
  • Any elective gastrointestinal surgery in patients with ascariasis should be delayed until they have been dewormed and adequately nourished. In particular, patients who live in endemic areas should be dewormed before and after elective cholecystectomy.

Medication

The goals of pharmacotherapy are to eradicate infestation, to prevent complications, and to reduce morbidity.

Anthelmintic agents

Parasite biochemical pathways are sufficiently different from the human host to allow selective interference by chemotherapeutic agents in relatively small doses.


Albendazole (Albenza)

First DOC. A benzimidazole carbamate drug that inhibits tubulin polymerization, resulting in degeneration of cytoplasmic microtubules. Decreases ATP production in worms, causing energy depletion, immobilization, and, finally, death. Converted in the liver to its primary metabolite, albendazole sulfoxide. Less than 1% of the primary metabolite is excreted in the urine. Plasma level is noted to rise significantly (as much as 5-fold) when ingested after high-fat meal. Experience with patients <6 y is limited.
To avoid inflammatory response in CNS, patient must also be started on anticonvulsants and high-dose glucocorticoids.
Well tolerated and does not appear to increase risk of worm obstruction.

Adult

400 mg PO single dose

Pediatric

Administer as in adults

Carbamazepine and phenytoin may decrease effects of albendazole; cimetidine may increase albendazole levels

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Adjust dose in hepatic impairment


Mebendazole (Vermox)

Well tolerated and does not appear to increase risk of worm obstruction. Causes worm death by selectively and irreversibly blocking uptake of glucose and other nutrients in susceptible adult intestine where helminths dwell.

Adult

500 mg PO once or 100 mg PO bid for 3 d

Pediatric

Administer as in adults

Coadministration with carbamazepine may decrease efficacy; dexamethasone, cimetidine, and praziquantel may increase toxicity

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Discontinue use if LFTs increase significantly (resume when levels decrease to pretest values); abdominal pain, nausea, vomiting, diarrhea, dizziness, vertigo, fever, increased intracranial pressure, and alopecia may occur


Pyrantel pamoate (Pin-Rid, Reese's Pinworm Medicine)

Neuromuscular blocking agent used to slowly paralyze worm to be eliminated from GI tract. May be DOC during pregnancy.

Adult

11 mg/kg PO to maximum of 1 g

Pediatric

<2 years: Do not use
>2 years: Administer as in adults

In ascariasis, pyrantel and piperazine are mutually antagonistic and should not be used concomitantly; theophylline serum levels may increase in pediatric patients following pyrantel pamoate administration

Documented hypersensitivity; hepatic disease

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in liver impairment, anemia, and malnutrition

More on Ascariasis

Overview: Ascariasis
Differential Diagnoses & Workup: Ascariasis
Treatment & Medication: Ascariasis
Follow-up: Ascariasis
Multimedia: Ascariasis
References

References

  1. Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet. May 6 2006;367(9521):1521-32. [Medline].

  2. Peng W, Yuan K, Hu M, et al. Recent insights into the epidemiology and genetics of Ascaris in China using molecular tools. Parasitology. Mar 2007;134:325-30. [Medline].

  3. Peng W, Zhou X, Gasser RB. Ascaris egg profiles in human faeces: biological and epidemiological implications. Parasitology. Sep 2003;127:283-90. [Medline].

  4. Le Hesran JY, Akiana J, Ndiaye el HM, et al. Severe malaria attack is associated with high prevalence of Ascaris lumbricoides infection among children in rural Senegal. Trans R Soc Trop Med Hyg. Jul 2004;98(7):397-9. [Medline].

  5. Geissler PW, Mwaniki D, Thiong F, et al. Geophagy as a risk factor for geohelminth infections: a longitudinal study of Kenyan primary schoolchildren. Trans R Soc Trop Med Hyg. Jan-Feb 1998;92(1):7-11. [Medline].

  6. Nejsum P, Parker ED, Frydenberg J, et al. Ascariasis is a zoonosis in denmark. J Clin Microbiol. Mar 2005;43(3):1142-8. [Medline].

  7. Do TT, Molbak K, Phung DC, et al. Helminth infections among people using wastewater and human excreta in peri-urban agriculture and aquaculture in Hanoi, Vietnam. Trop Med Int Health. Dec 2007;12 Suppl 2:82-90. [Medline].

  8. Oninla SO, Owa JA, Onayade AA, et al. Intestinal helminthiases among rural and urban schoolchildren in south-western Nigeria. Ann Trop Med Parasitol. Dec 2007;101(8):705-13. [Medline].

  9. Gangopadhyay AN, Upadhyaya VD, Gupta DK, et al. Conservative treatment for round worm intestinal obstruction. Indian J Pediatr. Dec 2007;74(12):1085-7. [Medline].

  10. van der Hoek W, De NV, Konradsen F, et al. Current status of soil-transmitted helminths in Vietnam. Southeast Asian J Trop Med Public Health. 2003;34 Suppl 1:1-11. [Medline].

  11. Sanai Fm, Al-Karawi MA. Biliary Ascariasis: Report of a Complicated Case and Literature Review. Saudi Journal of Gastroenterology. 2007/01;13:25-32.

  12. Shah OJ, Dar MA, Wani NA, et al. Biliary ascariasis as a cause of post-cholecystectomy syndrome in an endemic area. Dig Surg. 2004;21(2):108-13; discussion 113. [Medline].

  13. Donnen P, Brasseur D, Dramaix M, et al. Vitamin A supplementation but not deworming improves growth of malnourished preschool children in eastern Zaire. J Nutr. Aug 1998;128(8):1320-7. [Medline].

  14. Galvan-Ramirez ML, Rivera N, Loeza ME, et al. Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico. J Helminthol. Sep 2007;81(3):255-9. [Medline].

  15. Hosain GM, Saha S, Begum A. Impact of sanitation and health education on intestinal parasite infection among primary school aged children of Sherpur, Bangladesh. Trop Doct. Jul 2003;33(3):139-43. [Medline].

  16. Tsuji N, Suzuki K, Kasuga-Aoki H, et al. Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum. Infect Immun. Sep 2003;71(9):5314-23. [Medline].

  17. Saathoff E, Olsen A, Kvalsvig JD, et al. Patterns of geohelminth infection, impact of albendazole treatment and re-infection after treatment in schoolchildren from rural KwaZulu-Natal/South-Africa. BMC Infect Dis. Aug 13 2004;4:27. [Medline][Full Text].

  18. Albright JW, Basaric-Keys J. Instruction in behavior modification can significantly alter soil-transmitted helminth (STH) re-infection following therapeutic de-worming. Southeast Asian J Trop Med Public Health. Jan 2006;37(1):48-57. [Medline].

  19. Bradley JE, Jackson JA. Immunity, immunoregulation and the ecology of trichuriasis and ascariasis. Parasite Immunol. Nov-Dec 2004;26(11-12):429-41. [Medline].

  20. Choudhury SY, Kaiser MS. Varied presentation of biliary ascariasis and its consequences. Mymensingh Med J. Jul 2006;15(2):150-2. [Medline].

  21. Cleary JD, Graham D, Lushbaugh WB, et al. Single low-dose mebendazole administered quarterly for ascaris treatment. Am J Med Sci. Jun 2007;333(6):340-5. [Medline].

  22. Crompton DWT. Gastrointestinal Nematodes-Ascaris, Hookworm, Trichuris, and Enterobius. Topley and Wilson's Microbiology and Microbial Infections. 1998;Volume 5-Parasitology:561-580.

  23. Cunha BA. Antibiotic Essentials. Royal Oak, Mich: Physicians Press; 2005.

  24. de Silva NR, Guyatt HL, Bundy DA. Worm burden in intestinal obstruction caused by Ascaris lumbricoides. Trop Med Int Health. Feb 1997;2(2):189-90. [Medline].

  25. Holland CV, O'Shea E, Asaolu SO, et al. A cost-effectiveness analysis of anthelminthic intervention for community control of soil-transmitted helminth infection: levamisole and Ascaris lumbricoides. J Parasitol. Aug 1996;82(4):527-30. [Medline].

  26. Hotez PJ, Zheng F, Long-qi X, et al. Emerging and reemerging helminthiases and the public health of China. Emerg Infect Dis. Jul-Sep 1997;3(3):303-10. [Medline].

  27. Kakihara D, Yoshimitsu K, Ishigami K, et al. Liver lesions of visceral larva migrans due to Ascaris suum infection: CT findings. Abdom Imaging. Sep-Oct 2004;29(5):598-602. [Medline].

  28. Khuroo MS. Ascariasis. Gastroenterol Clin North Am. Sep 1996;25(3):553-77. [Medline].

  29. Legesse M, Erko B, Medhin G. Comparative efficacy of albendazole and three brands of mebendazole in the treatment of ascariasis and trichuriasis. East Afr Med J. Mar 2004;81(3):134-8. [Medline].

  30. Maruyama H, Nawa Y, Noda S, et al. An outbreak of ascariasis with marked eosinophilia in the southern part of Kyushu District, Japan, caused by infection with swine ascaris. Southeast Asian J Trop Med Public Health. 1997;28 Suppl 1:194-6. [Medline].

  31. Misra SP, Dwivedi M. Endoscopy-assisted emergency treatment of gastroduodenal and pancreatobiliary ascariasis. Endoscopy. Sep 1996;28(7):629-32. [Medline].

  32. Salman AB. Management of intestinal obstruction caused by ascariasis. J Pediatr Surg. Apr 1997;32(4):585-7. [Medline].

  33. Sandouk F, Haffar S, Zada MM, et al. Pancreatic-biliary ascariasis: experience of 300 cases. Am J Gastroenterol. Dec 1997;92(12):2264-7. [Medline].

  34. Schuster DI, Belin RP, Parker JC Jr, Burke JA, Jona JZ. Ascariasis--its complications, unusual presentations and surgical approaches. South Med J. Feb 1977;70(2):176-8. [Medline].

  35. Soomro MA, Akhtar J. Non-operative management of intestinal obstruction due to ascaris lumbricoides. J Coll Physicians Surg Pak. Feb 2003;13(2):86-9. [Medline].

  36. Steinberg R, Davies J, Millar AJ, et al. Unusual intestinal sequelae after operations for Ascaris lumbricoides infestation. Pediatr Surg Int. Apr 2003;19(1-2):85-7. [Medline].

  37. Villamizar E, Mendez M, Bonilla E, et al. Ascaris lumbricoides infestation as a cause of intestinal obstruction in children: experience with 87 cases. J Pediatr Surg. Jan 1996;31(1):201-4; discussion 204-5. [Medline].

  38. Zargar SA, Khan BA, Javid G, et al. Endoscopic management of early postoperative biliary ascariasis in patients with biliary tract surgery. World J Surg. Jul 2004;28(7):712-5. [Medline].

Further Reading

Keywords

ascariasis, helminthic infection, Ascaris lumbricoides, A lumbricoides, nematodes, roundworm, chronic ascariasis, acute ascariasis, biliary ascariasis, ascarids, geophagy, night soil, Ascaris lumbricoides suum, A lumbricoides suum, A suum, pig manure

Contributor Information and Disclosures

Author

David R Haburchak, MD, Program Director, Professor, Department of Internal Medicine, Division of Infectious Disease, Medical College of Georgia
David R Haburchak, MD is a member of the following medical societies: Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Medical Editor

Jeffrey D Band, MD, Clinical Professor of Medicine, Wayne State University School of Medicine; Director, Division of Infectious Diseases and International Medicine, William Beaumont Hospital Corporation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Richard B Brown, MD, FACP, Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine
Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.